SCHEMBL788022

SCHEMBL788022

COC(=O)[C@@H]1CC(O)CN1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.42
CHRNA4 P43681 2/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA7 P36544 1/20 0.42
DPP4 P27487 4/20 0.40
DPP8 Q6V1X1 4/20 0.40
DPP9 Q86TI2 4/20 0.40
SMYD3 Q9H7B4 1/20 0.38
KMT2A Q03164 1/20 0.35
CHEK2 O96017 2/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
ALOX15 P16050 1/20 0.33
CYP2C19 P33261 1/20 0.33
SLC1A3 P43003 1/20 0.33
SLC1A2 P43004 1/20 0.33
SLC1A1 P43005 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1439294 1.00 CHRNB2 (0.42) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL699327 1.00 CHRNB2 (0.42) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL3547377 1.00 CHRNB2 (0.42) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL729546 1.00 CHRNB2 (0.42) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL3534892 1.00 CHRNB2 (0.42) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL3542501 1.00 CHRNB2 (0.42) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL1303905 1.00 CHRNB2 (0.42) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL589711 1.00 CHRNB2 (0.42) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
Hydrochloric Acid SCHEMBL833267 0.98 CHRNB2 (0.41) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
Hydrochloric Acid SCHEMBL3862327 0.98 CHRNB2 (0.41) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 522 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025124444-A1 USE OF HYDROXYPROLINE AND DERIVATIVE THEREOF, BIOLOGICAL HERBICIDE, BROAD-SPECTRUM HERBICIDE, AND WEED CONTROL METHOD 三亚市国家耐盐碱水稻技术创新中心 2025-06-19 WO claimed
CN-120130489-A Application of hydroxyproline and derivatives thereof, biological herbicide, broad-spectrum herbicide and weed control method 三亚市国家耐盐碱水稻技术创新中心 2025-06-13 CN claimed
US-12319699-B2 L-proline sulfonamide derivatives comprising pyrazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazine system, method of manufacturing thereof, uses thereof and pharmaceutical composition comprising the same UNIWERSYTET MEDYCZNY W BIALYMSTOKU (PL) 2025-06-03 US claimed
EP-3886990-B1 NOVEL L-PROLINE SULFONAMIDE DERIVATIVES COMPRISING PYRAZOLO[4,3- E]TETRAZOLO[4,5-B][1,2,4]TRIAZINE SYSTEM, METHOD OF MANUFACTURING THEREOF, USES THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME UNIV MEDYCZNY W BIALYMSTOKU (PL) 2023-06-07 EP claimed
US-20220017529-A1 NOVEL L-PROLINE SULFONAMIDE DERIVATIVES COMPRISING PYRAZOLO[4,3- E]TETRAZOLO[4,5-B][1,2,4]TRIAZINE SYSTEM, METHOD OF MANUFACTURING THEREOF, USES THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME UNIWERSYTET MEDYCZNY W LUBLINIE (PL) 2022-01-20 US claimed
EP-3886990-A1 NOVEL L-PROLINE SULFONAMIDE DERIVATIVES COMPRISING PYRAZOLO[4,3- E]TETRAZOLO[4,5-B][1,2,4]TRIAZINE SYSTEM, METHOD OF MANUFACTURING THEREOF, USES THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Uniwersytet Medyczny W Bialymstoku (PL) 2021-10-06 EP claimed
WO-2020111956-A1 NOVEL L-PROLINE SULFONAMIDE DERIVATIVES COMPRISING PYRAZOLO[4,3- E]TETRAZOLO[4,5-B][1,2,4]TRIAZINE SYSTEM, METHOD OF MANUFACTURING THEREOF, USES THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME UNIWERSYTET MEDYCZNY W BIAŁYMSTOKU (PL) 2020-06-04 WO claimed
CN-102250014-A Method for preparing chiral 1-benzyloxycarbonyl hexahydropyridazine-3-carboxylic acid and chiral 1, 2-dibenzyloxycarbonyl hexahydropyridazine-3-carboxylic acid SHANGHAI AOBO BIO PHARMACEUTICAL TECH CO LTD 2011-11-23 CN claimed
EP-1496891-B1 METHODS FOR MODULATING PHOTOTOXICITY UNIV ARIZONA STATE (US) 2011-07-20 EP claimed
US-7479536-B1 Chiral, charged peptide nucleic acid oligomers from cyclic monomers COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2009-01-20 US claimed
CN-1646121-A Methods for modulating phototoxicity UNIV ARIZONA (US) 2005-07-27 CN claimed
US-20050042188-A1 Method for modulating phototoxicity WONDRAK GEORG T (US) 2005-02-24 US claimed
EP-1496891-A2 METHODS FOR MODULATING PHOTOTOXICITY University Of Arizona (US) 2005-01-19 EP claimed
US-20030223941-A1 Methods for modulating phototoxicity NIADYNE, INC. 2003-12-04 US claimed
WO-2003088909-A2 METHODS FOR MODULATING PHOTOTOXICITY UNIVERSITY OF ARIZONA (US) 2003-10-30 WO claimed
CN-122059930-A Cdc25 phosphatase degradation agent based on quinoline dione skeleton, and preparation method and application thereof 山东大学 2026-05-19 CN disclosed
US-12622917-B2 High-activity Wnt pathway inhibitor compound ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2026-05-12 US disclosed
EP-0042639-A2 Azido, imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids having hypotensive activity E.R. Squibb & Sons, Inc. (US) 1981-12-30 EP disclosed
US-4308388-A HYPOTENSIVE; INHIBITS CONVERSION OF ANGIOTENSIN I TO ANGIOTENSIN II E. R. SQUIBB & SONS, INC. (US) 1981-12-29 US disclosed
US-4296033-A INHIBITOR OF ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENT E. R. SQUIBB & SONS, INC. (US) 1981-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319699-B2 L-proline sulfonamide derivatives comprising pyrazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazine system, method of manufacturing thereof, uses thereof and pharmaceutical composition comprising the same APC, PGA5, API5 CHRNB2 4879/4885CHRNA4 4875/4885CHRNB4 4880/4885
US-20220017529-A1 NOVEL L-PROLINE SULFONAMIDE DERIVATIVES COMPRISING PYRAZOLO[4,3- E]TETRAZOLO[4,5-B][1,2,4]TRIAZINE SYSTEM, METHOD OF MANUFACTURING THEREOF, USES THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME PGA5, APC, API5 CHRNB2 4880/4885CHRNA4 4873/4885CHRNB4 4879/4885
US-12622917-B2 High-activity Wnt pathway inhibitor compound WNT1, WNT3, WNT3A CHRNB2 2602/4885CHRNA4 2840/4885CHRNB4 2905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.